logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
1/9/2018 7:12:28 AM Axsome: IDMC Recommend COAST-1 Trial Be Continued To Full Enrollment And CREATE-1 Trial Be Stopped For Futility
12/14/2017 7:11:40 AM Axsome Collaborates With Duke University To Evaluate AXS-05 In Phase 2 Clinical Trial In Smokers Attempting To Quit
12/1/2017 7:05:36 AM Axsome Therapeutics Announces $9.5 Mln Direct Offering
11/8/2017 7:08:46 AM Axsome Therapeutics Posts Q3 Net Loss Of $6.4 Mln Or $0.27/share
9/7/2017 7:24:31 AM Axsome Therapeutics Says Interim Analysis Of Phase 3 CREATE-1 Trial Of AXS-02 In CRPS Expected Year-end 2017
8/9/2017 7:19:51 AM Axsome Therapeutics Q2 Net Loss $7.1 Mln Or $0.30/shr Vs. Net Loss $6.8 Mln Or $0.36/shr Last Year
7/17/2017 7:04:47 AM Axsome Therapeutics Begins Phase 2/3 Trial Of AXS-05 For Alzheimer’s Disease Agitation
7/6/2017 7:01:54 AM Axsome Therapeutics Says Appoints John Golubieski As CFO, Effective Aug. 4
5/9/2017 7:15:01 AM Axsome Therapeutics Posts Q1 Net Loss Of $8 Mln Or $0.41/share
5/8/2017 7:13:03 AM Axsome Therapeutics Gets FDA Fast Track Designation For AXS-05 For Alzheimer’s Disease Agitation
3/29/2017 7:04:46 AM Axsome Therapeutics Announces Full Exercise Of Underwriter’s Option To Purchase Additional 561,497 Shares
3/21/2017 9:22:08 AM Axsome Therapeutics Announces Pricing Of Underwritten Public Offering Of 3.74 Mln Shares At $3.74/shr
3/20/2017 4:12:23 PM Axsome Therapeutics Announces Proposed Public Offering Of Common Stock